List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Celiac Disease - Overview
Celiac Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Celiac Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Celiac Disease - Companies Involved in Therapeutics Development
Ahead Therapeutics SL
Amgen Inc
Amyra Biotech AG
Anokion SA
AnTolRx Inc
Bioniz Therapeutics Inc
GlaxoSmithKline Plc
ImmunogenX LLC
ImmunoMolecular Therapeutics LLC
ImmusanT Inc
Innovate Biopharmaceuticals Inc
Parvus Therapeutics Inc
Precigen Inc
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Topas Therapeutics GmbH
Vactech Oy
Zedira GmbH
Celiac Disease - Drug Profiles
AG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMY-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1715 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERW-1041E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KAN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latiglutenase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Oncology and Tropical Spastic Paraparesis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexvax-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HLA-DQ2 for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-5202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-1227 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-754 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Celiac Disease - Dormant Projects
Celiac Disease - Discontinued Products
Celiac Disease - Product Development Milestones
Featured News & Press Releases
Feb 27, 2020: Anokion announces initiation of patient dosing in Phase 1 clinical trial of KAN-101 in celiac disease
Feb 19, 2020: Innovate Biopharmaceuticals announces acceptance of three abstracts for the 2020 Digestive Disease Week (DDW) conference
Feb 14, 2020: ImmunogenX starts enrolment in Phase IIb celiac disease study
Jan 21, 2020: Anokion announces FDA clearance of IND application for its lead program in celiac disease
Oct 22, 2019: Takeda Pharmaceutical: New treatment may reverse celiac disease
Aug 19, 2019: ActoBio Therapeutics receives IND green light for new antigen-specific immunotherapy study aimed at improving celiac patients tolerance of gluten
Aug 13, 2019: Innovate Biopharmaceuticals announces first patient dosed in the first phase 3 clinical trial for patients with celiac disease
Jul 15, 2019: Innovate Biopharmaceuticals announces corporate update and expected date for second quarter earnings release
Jun 25, 2019: ImmusanT discontinues phase 2 clinical trial for Nexvax2 in patients with celiac disease
Jun 24, 2019: Innovate Biopharmaceuticals expands its management team with the addition of Ed Sitar as Its Chief Financial Officer
Jun 10, 2019: Innovate Biopharmaceuticals announces the start of the first phase 3 clinical trial in Celiac Disease
May 21, 2019: ImmusanT presents early evidence supporting its lead therapeutic vaccine candidate during the Digestive Disease Week Annual Conference2019
Apr 09, 2019: ImmunogenX receives major grant from the National Institutes of Health (NIH) to conduct a clinical trial for Latiglutenase
Apr 02, 2019: Innovate Biopharmaceuticals to announce first quarter 2019 financial results and to provide operational progress updates on April 29, 2019
Mar 21, 2019: ImmusanT to present and participate in multiple upcoming industry and scientific conferences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Celiac Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Celiac Disease - Pipeline by Ahead Therapeutics SL, H1 2020
Celiac Disease - Pipeline by Amgen Inc, H1 2020
Celiac Disease - Pipeline by Amyra Biotech AG, H1 2020
Celiac Disease - Pipeline by Anokion SA, H1 2020
Celiac Disease - Pipeline by AnTolRx Inc, H1 2020
Celiac Disease - Pipeline by Bioniz Therapeutics Inc, H1 2020
Celiac Disease - Pipeline by GlaxoSmithKline Plc, H1 2020
Celiac Disease - Pipeline by ImmunogenX LLC, H1 2020
Celiac Disease - Pipeline by ImmunoMolecular Therapeutics LLC, H1 2020
Celiac Disease - Pipeline by ImmusanT Inc, H1 2020
Celiac Disease - Pipeline by Innovate Biopharmaceuticals Inc, H1 2020
Celiac Disease - Pipeline by Parvus Therapeutics Inc, H1 2020
Celiac Disease - Pipeline by Precigen Inc, H1 2020
Celiac Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Celiac Disease - Pipeline by Theravance Biopharma Inc, H1 2020
Celiac Disease - Pipeline by Topas Therapeutics GmbH, H1 2020
Celiac Disease - Pipeline by Vactech Oy, H1 2020
Celiac Disease - Pipeline by Zedira GmbH, H1 2020
Celiac Disease - Dormant Projects, H1 2020
Celiac Disease - Dormant Projects, H1 2020 (Contd..1), H1 2020
Celiac Disease - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Celiac Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

Companies Mentioned
• Ahead Therapeutics SL
• Amgen Inc
• Amyra Biotech AG
• Anokion SA
• AnTolRx Inc
• Bioniz Therapeutics Inc
• GlaxoSmithKline Plc
• ImmunogenX LLC
• ImmunoMolecular Therapeutics LLC
• ImmusanT Inc
• Innovate Biopharmaceuticals Inc
• Parvus Therapeutics Inc
• Precigen Inc
• Takeda Pharmaceutical Co Ltd
• Theravance Biopharma Inc
• Topas Therapeutics GmbH
• Vactech Oy
• Zedira GmbH